Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report) was the recipient of a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 184,114 shares, a growth of 56.8% from the August 31st total of 117,438 shares. Based on an average daily volume of 4,206 shares, the short-interest ratio is presently 43.8 days. Currently, 0.2% of the company’s stock are sold short.
Oxford BioMedica Stock Performance
Shares of OTCMKTS:OXBDF remained flat at $6.65 during trading on Thursday. 20,000 shares of the stock were exchanged, compared to its average volume of 2,470. The stock has a 50 day moving average of $7.01 and a 200-day moving average of $7.69. Oxford BioMedica has a twelve month low of $5.80 and a twelve month high of $12.61.
Wall Street Analysts Forecast Growth
Separately, Zacks Research raised shares of Oxford BioMedica to a “hold” rating in a report on Wednesday, July 22nd. One investment analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock presently has an average rating of “Hold”.
Oxford BioMedica Company Profile
Oxford BioMedica plc is a United Kingdom-based contract development and manufacturing organization (CDMO) focused on cell and gene therapies. The company helps biotechnology and pharmaceutical customers develop, test, and manufacture advanced therapies, with expertise in viral-vector technologies used to deliver genetic material into cells.
Its services include process and analytical development, clinical and commercial manufacturing, quality testing, regulatory support, and related research services.
See Also
- Five stocks we like better than Oxford BioMedica
- Hobby Boom or Travel Bust? Here Are 3 Stocks to Ride the Trend
- Jabil’s Double-Beat and Raise Is a Signal That This Rally Will Continue
- Anthropic’s IPO Could Put Amazon’s and Alphabet’s Paper Profits to the Test
- Microsoft’s AI Spending Didn’t Change—Wall Street’s View of It Did
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
